The Mundipharma network of independent associated companies has introduced the type-two diabetes mellitus treatments Invokana (canagliflozin) and Vokanamet (canagliflozin, metformin) in Norway, it was reported yesterday.
In line with the collaboration with Janssen Pharmaceutica NV, Mundipharma now distributes and markets these treatments across 18 countries in the European Economic Area and Switzerland. With the launch in Norway, Invokana and Vokanamet are now offered across the whole of Scandinavia, following launches in Sweden and Denmark.
Invokana is a once-daily oral tablet and part of the sodium glucose co-transporter 2 (SGLT2) inhibitor class and has been approved in the European Union since 2013. Vokanamet integrates two oral glucose-lowering medicinal products (canagliflozin and metformin) with different and complementary mechanisms of action.
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Aprecia names new chief commercial officer
Insulet's Omnipod 5 integration with Abbott FreeStyle Libre 2 Plus Sensor secures CE Mark approval
Kyowa Kirin enrols first subject in phase two tivozanib eye drops (KHK4951) clinical trial
Novo Nordisk to boost manufacturing capacity with acquisition of three fill-finish sites
Breye Therapeutics commences phase 1b/2a danegaptide clinical trial
DexCom Inc breaks ground on new manufacturing facility in Ireland
VibroSense Dynamics AB secures provisional patent for chemotherapy-induced nerve damage prediction
Innovent Biologics signs collaboration agreement with Sanegene Bio USA
Japan approves GSK's filing for Arexvy vaccination for at-risk adults
Arecor Therapeutics plc extends collaboration with Eli Lilly
OptiBiotix Health partners with Ravenswood for SlimBiome distribution in Australia and New Zealand
Boehringer Ingelheim granted European approval of oral liquid medication for feline diabetes